Physician profile
Mark A Kirkpatrick
NPI 1235182304
$2,318.77
in general payments reported to CMS, 2019-2025
32 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $293 · 2021: $529 · 2022: $420 · 2023: $244 · 2024: $393 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $450.91 | 2022-2025 | |
| Lilly USA, LLC | $306.83 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $216.68 | 2020-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.48 | 2019-2023 | Jardiance |
| Shield Therapeutics INC | $124.22 | 2024 | |
| Novartis Pharmaceuticals Corporation | $108.57 | 2019-2023 | |
| Glaxosmithkline, LLC. | $95.23 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $71.30 | 2019-2024 | |
| Abbott Laboratories | $69.80 | 2021-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $62.82 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.51 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $56.75 | 2020-2022 | |
| Novo Nordisk INC | $56.52 | 2020-2022 | |
| Medtronic, INC. | $55.65 | 2025 | Endurant Iis |
| Astellas Pharma US INC | $52.47 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $41.12 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $38.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.70 | 2020 | |
| Amgen INC. | $28.66 | 2021-2023 | Repatha |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.18 | 2022 | |
| Axsome Therapeutics, INC. | $27.55 | 2023 | Auvelity |
| Nestle Healthcare Nutrition INC. | $24.79 | 2022 | |
| Cipher Pharmaceuticals US LLC | $23.91 | 2025 | Spinosad, Natroba |
| Paratek Pharmaceuticals, INC. | $20.79 | 2020 | |
| Lundbeck LLC | $15.67 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $15.24 | 2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.67 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $13.16 | 2021 | |
| Mylan Specialty L.P. | $12.88 | 2022 | |
| Sumitomo Pharma America, INC. | $12.60 | 2023 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $12.42 | 2022 | |
| Allergan, INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kirkpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.